Age-related distribution of homologous recombination deficiency in advanced ovarian carcinoma: a large real-world French cohort.

Fiche publication

Date publication

juin 2026

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr BOIDOT Romain , Dr CHARON-BARRA Céline , Dr DERANGERE Valentin , Dr ALBUISSON Juliette , Dr GOUSSOT Vincent

Tous les auteurs :
Gertych W, Trecourt A, Morineau F, Beacco P, Brasselet A, Carnet M, Chevriaux A, Chevrier S, Dupasquier M, Gibeaud A, Albuisson J, Comte A, Derangère V, Goussot V, Arnould L, Bergeron A, Beltjens F, Charon-Barra C, Vinson C, Boidot R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42462286

Résumé

Tumor genetic testing for BRCA and homologous recombination repair is essential for guiding maintenance therapy in high-grade non-mucinous ovarian carcinomas. While clinical trials (PAOLA-1, PRIMA, ATHENA-MONO, PRIME) have reported homologous recombination deficiency rates of 44% to 67% in cohorts with a median age of 61, real-world data suggest age-related variations. We aimed to evaluate homologous recombination deficiency prevalence in a large French population and hypothesized a distribution pattern similar to the recent German findings published in 2022, in which older age correlated with lower homologous recombination deficiency rates.